Merck & Co., Inc. (NYSE:MRK) Doesn’t Seem Hopeful About Sugammadex Injection Approval

Like every other prominent company in the healthcare business, Merck & Co., Inc. (NYSE:MRK) is chasing behind development of new drugs that can bring some needful changes in the world. But U.S. regulatory conditions don’t seem favorable to its approach. As per the reports, Merck recently announced that it didn’t have high hopes for approval of Sugammadex Injection.

Analyst identify potential hold signals in MRK.

Insights On The Matter:

The announcement came after U.S. regulators told Merck that they needed more time and inspections to check out sites in regard to the study of the drug that could reverse the deadly effects of anesthesia. Even though U.S. Food and Drug Administration has not yet given any official statement, but Merck expects a negative response from them. The final response will be delivered to the company by April 22, 2015. As per the reports, such complete response letters are meant to communicate that FDA is not willing to give the green signal to any company.

There was a request made by Merck in order to schedule a marketing meeting with the independent FDA medical advisory panel on March 18. But it has been canceled by FDA, which is a clear sign that it’s not interested in its proposal. The company added that despite this negative response from Merck, Merck would continue to work with FDA until this issue is cleared. Sugammadex is a well-known drug that improves the muscle relaxants after surgery has already been approved in more than 50 countries without any hassle, but conditions don’t look favorable in U.S., at least not now.

A renowned brokerage company Cowen & Co. has estimated that if the U.S. government approves Sugammadex now, then it can generate total annual sales of $550 million by year 2020. The entire country is in need of such drugs, and response of FDA is beyond anyone’s understanding. The management of Merck & Co., Inc. (NYSE:MRK) hopes that the situation will improve in the near future.


Enter Email Here

FREE Report On This Stock

To reeive our FREE investing report and weekly alerts, enter your information below!

Your privacy is important to us. We’ll never share your information.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:





Erica is a graduate of New York University's school of Journalism. She joined US Markets Daily as a general assignment reporter in January of 2008.